儿童白塞综合征44例临床特征分析
Analysis of Clinical Features in 44 Pediatric Cases of Behçet’s Syndrome
DOI: 10.12677/acm.2025.1582392, PDF,   
作者: 赵 硕*, 常 红#:青岛大学附属医院儿童肾脏风湿免疫科,山东 青岛
关键词: 白塞综合征儿童临床特征Behçet’s Syndrome Pediatrics Clinical Characteristics
摘要: 目的:分析总结44例白塞综合征(Behçet’s syndrome, BS)患儿临床特征,提高临床医生对该病的认识及诊治水平。方法:回顾性分析2013年6月至2023年6月青岛大学附属医院儿童肾脏风湿免疫科住院治疗的44例儿童BS病例资料,总结其临床表现、实验室及辅助检查、治疗方案及转归情况。结果:44例BS患儿中,男性24例、女性20例(男女比1.2:1)。发病年龄3~17岁(均值10.1 ± 4.0岁)。42例患儿(95.5%)出现口腔溃疡,30例患儿(68.2%)出现生殖器溃疡,女性患儿的生殖器溃疡发生率显著高于男性(P < 0.001)。16例患儿(36.4%)出现皮疹,10例患儿(22.7%)眼部受累,9例患儿(20.5%)伴有关节症状,2例患儿(4.5%)伴有神经系统症状,1例患儿(2.2%)出现肺栓塞。根据2014年白塞病国际临床评分标准(International Criteria for Behçet’s Disease, ICBD)诊断标准,39例(88.6%)患儿符合该标准,余5例患儿经消化内镜病理活检确诊。44例患儿中38例(86.4%)治疗后症状缓解。27例患儿(61.4%)治疗方案包含沙利度胺,23例患儿症状缓解。9例(20.5%)治疗方案中包含糖皮质激素,6例缓解。5例(11.4%)患儿加用阿达木单抗。4例缓解。结论:儿童BS临床表现以复发性口腔溃疡、生殖器溃疡、葡萄膜炎、皮疹及消化道症状为特征。女性患儿生殖器溃疡发生率高于男性,以沙利度胺和糖皮质激素为基础的个体化综合治疗可显著缓解症状。
Abstract: Objective: To analyze and summarize the clinical characteristics of 44 pediatric patients with Behçet’s syndrome (BS) in order to improve clinicians’ diagnosis and treatment of this disease. Methods: A retrospective analysis was conducted on the clinical data of 44 pediatric BS cases hospitalized in the Department of Pediatric Nephrology, Rheumatology, and Immunology at the Affiliated Hospital of Qingdao University from June 2013 to June 2023. Their clinical manifestations, laboratory and auxiliary examinations, treatment regimens, and outcomes were summarized. Results: Among the 44 pediatric BS patients, there were 24 males and 20 females (male-to-female ratio 1.2:1). The age of onset ranged from 3 to 17 years (mean 10.1 ± 4.0 years). Oral ulcers occurred in 42 patients (95.5%), and genital ulcers in 30 patients (68.2%), with a significantly higher incidence of genital ulcers in female patients than in males (P < 0.001). Skin lesions occurred in 16 patients (36.4%), ocular involvement in 10 (22.7%), joint symptoms in 9 (20.5%), neurological symptoms in 2 (4.5%), and pulmonary embolism in 1 (2.2%). According to the 2014 International Criteria for Behçet’s Disease (ICBD), 39 patients (88.6%) met the diagnostic criteria; the remaining 5 cases were confirmed by gastrointestinal endoscopy and pathological biopsy. Symptom remission was achieved in 38 (86.4%) of the 44 patients after treatment. The treatment regimen included thalidomide for 27 patients (61.4%), with 23 achieving symptom remission. Glucocorticoids were included in the treatment for 9 patients (20.5%), with 6 achieving remission. Adalimumab was added for 5 patients (11.4%), with 4 achieving remission. Conclusion: The clinical manifestations of pediatric BS are characterized by recurrent oral ulcers, genital ulcers, uveitis, skin rashes, and gastrointestinal symptoms. The incidence of genital ulcers is higher in female patients than in males. Individualized comprehensive treatment based on thalidomide and glucocorticoids can significantly alleviate symptoms.
文章引用:赵硕, 常红. 儿童白塞综合征44例临床特征分析[J]. 临床医学进展, 2025, 15(8): 1516-1526. https://doi.org/10.12677/acm.2025.1582392

参考文献

[1] Emmi, G., Bettiol, A., Hatemi, G. and Prisco, D. (2024) Behçet’s syndrome. The Lancet, 403, 1093-1108. [Google Scholar] [CrossRef] [PubMed]
[2] Sakane, T., Takeno, M., Suzuki, N. and Inaba, G. (1999) Behçet’s Disease. New England Journal of Medicine, 341, 1284-1291. [Google Scholar] [CrossRef] [PubMed]
[3] Takeuchi, M., Kastner, D.L. and Remmers, E.F. (2015) The Immunogenetics of Behçet’s Disease: A Comprehensive Review. Journal of Autoimmunity, 64, 137-148. [Google Scholar] [CrossRef] [PubMed]
[4] 中国医师协会儿科医师分会风湿免疫学组. 中国儿童血管炎诊断与治疗系列专家共识之三——白塞综合征[J]. 中国实用儿科杂志, 2023, 38(6): 407-412.
[5] Koné-Paut, I. (2016) Behçet’s Disease in Children, an Overview. Pediatric Rheumatology, 14, Article No. 10. [Google Scholar] [CrossRef] [PubMed]
[6] Davatchi, F., Assaad‐Khalil, S., Calamia, K.T., Crook, J.E., Sadeghi‐Abdollahi, B., Schirmer, M., et al. (2013) The International Criteria for Behçet’s Disease (ICBD): A Collaborative Study of 27 Countries on the Sensitivity and Specificity of the New Criteria. Journal of the European Academy of Dermatology and Venereology, 28, 338-347. [Google Scholar] [CrossRef] [PubMed]
[7] Yildiz, M., Koker, O. and Kasapcopur, O. (2024) Juvenile Behçet Syndrome: A Contemporary View and Differential Diagnosis in Pediatric Practice. Current Opinion in Rheumatology, 37, 3-14. [Google Scholar] [CrossRef] [PubMed]
[8] Açarı, C., İşgüder, R., Torun, R., Makay, B. and Erbil Ünsal, Ş. (2022) Pediatric Behçet’s Disease: Experience of a Single Tertiary Center. Archives of Rheumatology, 38, 282-290. [Google Scholar] [CrossRef] [PubMed]
[9] Butbul Aviel, Y., Batu, E.D., Sözeri, B., Aktay Ayaz, N., Baba, L., Amarilyo, G., et al. (2020) Characteristics of Pediatric Behçet’s Disease in Turkey and Israel: A Cross-Sectional Cohort Comparison. Seminars in Arthritis and Rheumatism, 50, 515-520. [Google Scholar] [CrossRef] [PubMed]
[10] Koné-Paut, I., Yurdakul, S., Bahabri, S.A., Shafae, N., Ozen, S., Özdogan, H., et al. (1998) Clinical Features of Behçet’s Disease in Children: An International Collaborative Study of 86 Cases. The Journal of Pediatrics, 132, 721-725. [Google Scholar] [CrossRef] [PubMed]
[11] Gallizzi, R., Pidone, C., Cantarini, L., Finetti, M., Cattalini, M., Filocamo, G., et al. (2017) A National Cohort Study on Pediatric Behçet’s Disease: Cross-Sectional Data from an Italian Registry. Pediatric Rheumatology, 15, Article No. 84. [Google Scholar] [CrossRef] [PubMed]
[12] Nanthapisal, S., Klein, N.J., Ambrose, N., Eleftheriou, D. and Brogan, P.A. (2016) Paediatric Behçet’s Disease: A UK Tertiary Centre Experience. Clinical Rheumatology, 35, 2509-2516. [Google Scholar] [CrossRef] [PubMed]
[13] 中华医学会眼科学分会免疫学组, 中国医师协会眼科医师分会葡萄膜炎与免疫学组. 中国白塞综合征性葡萄膜炎临床诊疗专家共识(2023年) [J]. 中华眼科杂志, 2023, 59(5): 324-331.
[14] Kari, J.A. (2001) Behcet’s Disease in UK Children: Clinical Features and Treatment Including Thalidomide. Rheumatology, 40, 933-938. [Google Scholar] [CrossRef] [PubMed]
[15] Hamuryudan, V., Mat, C., Saip, S., Ozyazgan, Y., Siva, A., Yurdakul, S., et al. (1998) Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine, 128, 443-450. [Google Scholar] [CrossRef] [PubMed]
[16] Yasui, K., Uchida, N., Akazawa, Y., Nakamura, S., Minami, I., Amano, Y., et al. (2008) Thalidomide for Treatment of Intestinal Involvement of Juvenile-Onset Behçet Disease. Inflammatory Bowel Diseases, 14, 396-400. [Google Scholar] [CrossRef] [PubMed]
[17] Hatemi, G., Christensen, R., Bang, D., Bodaghi, B., Celik, A.F., Fortune, F., et al. (2018) 2018 Update of the EULAR Recommendations for the Management of Behçet’s Syndrome. Annals of the Rheumatic Diseases, 77, 808-818. [Google Scholar] [CrossRef] [PubMed]
[18] Giani, T., Luppino, A.F. and Ferrara, G. (2023) Treatment Options in Pediatric Behçet’s Disease. Pediatric Drugs, 25, 165-191. [Google Scholar] [CrossRef] [PubMed]